Table 1.
Distribution of patient characteristics and outcomes.
| Covariates and outcomes | n (%) or Median (Q1–Q3) |
|---|---|
| CD4+ cell count (cells/μl) at cART initiation | |
| <200 | 1827 (44%) |
| 200–349 | 1311 (32%) |
| 350–499 | 591 (14%) |
| More than 500 | 391 (10%) |
| Sex | |
| Male | 3328 (80%) |
| Female | 792 (20%) |
| Age (years) | 42 (35–49) |
| Viral load (log10 copies/ml) at cART initiation, median (Q1-Q3) | 4.90 (4.38–5.00) |
| History of injection drug use | |
| No | 1839 (45%) |
| Yes | 1501 (36%) |
| Unknown | 780 (19%) |
| Follow-up (months) | 60 (34–95) |
| Adherence to therapy during the first 6 months on cART | |
| ≥95% | 3219 (78%) |
| 80 to <95% | 213 (5%) |
| 40 to <80% | 455 (11%) |
| 0 to <40% | 233 (6%) |
| Suppression at 9 months | |
| Yes | 2926 (71%) |
| No | 1194 (29%) |
| Drug resistance at cART initiation | |
| No | 4008 (97%) |
| Yes | 112 (3%) |
| Developing resistance to any class during follow-upa | |
| No | 3560 (89%) |
| Yes | 448 (11%) |
| Developing an AIDS-defining illness during follow-up | |
| No | 3815 (93%) |
| Yes | 305 (7%) |
| Status at the end of follow-up | |
| Alive | 2893 (70%) |
| Death | 492 (12%) |
| Loss to follow-up | 735 (18%) |
Q1: 25th percentile, Q3: 75th percentile. cART, combination anti-retroviral therapy.
a
Denominator is the number of patients without baseline resistance.